Literature DB >> 3756067

Sparteine oxidation is practically abolished in quinidine-treated patients.

R Brinn, K Brøsen, L F Gram, T Haghfelt, S V Otton.   

Abstract

In eight patients a sparteine-test was carried out immediately before and after 1 week of treatment with quinidine 600-800 mg day-1. Before treatment one patient was classified as a poor metaboliser (metabolic ratio: greater than or equal to 20), and seven patients as extensive metabolisers. During quinidine treatment, the formation of sparteine metabolites (2- and 5-dehydrosparteine) was practically abolished. Patients initially classified as extensive metabolisers thus exhibited the phenotype of poor metabolisers during quinidine treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3756067      PMCID: PMC1401116          DOI: 10.1111/j.1365-2125.1986.tb05250.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.

Authors:  T Leemann; P Dayer; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

Authors:  S V Otton; T Inaba; W Kalow
Journal:  Life Sci       Date:  1984-01-02       Impact factor: 5.037

3.  Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.

Authors:  A R Boobis; S Murray; G C Kahn; G M Robertz; D S Davies
Journal:  Mol Pharmacol       Date:  1983-03       Impact factor: 4.436

4.  The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.

Authors:  M S Lennard; P R Jackson; S Freestone; G T Tucker; L E Ramsay; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

5.  Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs.

Authors:  S V Otton; T Inaba; W Kalow
Journal:  Life Sci       Date:  1983-02-14       Impact factor: 5.037

6.  Oxidation phenotype--a major determinant of metoprolol metabolism and response.

Authors:  M S Lennard; J H Silas; S Freestone; L E Ramsay; G T Tucker; H F Woods
Journal:  N Engl J Med       Date:  1982-12-16       Impact factor: 91.245

7.  The genetic control of bufuralol metabolism in man.

Authors:  P Dayer; L Balant; F Courvoisier; A Kupfer; A Kubli; A Gorgia; J Fabre
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

Review 8.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

9.  Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade.

Authors:  T C Raghuram; R P Koshakji; G R Wilkinson; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

10.  Sparteine metabolism in Canadian Caucasians.

Authors:  A Vinks; T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

View more
  27 in total

1.  Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias.

Authors:  U M Birgersdotter; W Wong; J Turgeon; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

2.  Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents.

Authors:  Eric Guenin; Marianna Armogida; Dennis Riff
Journal:  Clin Drug Investig       Date:  2014-09       Impact factor: 2.859

3.  Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots.

Authors:  P R Jackson; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

4.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

6.  Substantial rise in sparteine metabolic ratio during haloperidol treatment.

Authors:  L F Gram; D Debruyne; V Caillard; J P Boulenger; J Lacotte; M Moulin; E Zarifian
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

7.  Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

Authors:  C Funck-Brentano; H K Kroemer; H Pavlou; R L Woosley; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

8.  Sparteine oxidation polymorphism in Greenlanders living in Denmark.

Authors:  K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

9.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

10.  Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.

Authors:  G Muralidharan; E M Hawes; G McKay; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.